These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22762141)

  • 1. Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection.
    Girardin F; Daali Y; Gex-Fabry M; Rebsamen M; Roux-Lombard P; Cerny A; Bihl F; Binek J; Moradpour D; Negro F; Desmeules J;
    J Viral Hepat; 2012 Aug; 19(8):568-73. PubMed ID: 22762141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.
    Hijikata M; Miyakawa H; Matsushita M; Kako M; Ohta Y; Mishiro S
    Biochem Biophys Res Commun; 2000 Apr; 270(3):922-6. PubMed ID: 10772926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
    Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
    J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.
    Duclos-Vallée JC; Nishioka M; Hosomi N; Arima K; Leclercq A; Bach JF; Yamamoto AM
    J Hepatol; 1998 Jun; 28(6):965-70. PubMed ID: 9672171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CYP2D6 in pregnancy.
    Wadelius M; Darj E; Frenne G; Rane A
    Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection.
    Ma Y; Peakman M; Lobo-Yeo A; Wen L; Lenzi M; Gäken J; Farzaneh F; Mieli-Vergani G; Bianchi FB; Vergani D
    Clin Exp Immunol; 1994 Jul; 97(1):94-9. PubMed ID: 8033426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.
    Miyakawa H; Kikazawa E; Abe K; Kikuchi K; Fujikawa H; Matsushita M; Kawaguchi N; Morizane T; Ohya K; Kako M
    Autoimmunity; 1999; 30(2):107-14. PubMed ID: 10435724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
    Klein R; Zanger UM; Berg T; Hopf U; Berg PA
    Clin Exp Immunol; 1999 Nov; 118(2):290-7. PubMed ID: 10540193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies.
    Duclos-Vallée JC; Hajoui O; Yamamoto AM; Jacz-Aigrain E; Alvarez F
    Gastroenterology; 1995 Feb; 108(2):470-6. PubMed ID: 7530671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
    Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.
    Sugimura T; Obermayer-Straub P; Kayser A; Braun S; Loges S; Alex B; Lüttig B; Johnson EF; Manns MP; Strassburg CP
    Autoimmunity; 2002 Dec; 35(8):501-13. PubMed ID: 12765476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos.
    Sosa-Macías M; Dorado P; Alanis-Bañuelos RE; Llerena A; Lares-Asseff I
    Pharmacology; 2010; 86(1):30-6. PubMed ID: 20588073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model.
    Hintermann E; Holdener M; Bayer M; Loges S; Pfeilschifter JM; Granier C; Manns MP; Christen U
    J Autoimmun; 2011 Nov; 37(3):242-53. PubMed ID: 21795021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
    Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
    Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.